Cargando…
Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study
INTRODUCTION: The actual rate of conversion surgery and its prognostic advantages remain unclear. This study aimed to assess the outcomes of salvage surgery after conversion therapy with triple therapy (transcatheter arterial chemoembolization [TACE] combined with lenvatinib plus anti-PD-1 antibodie...
Autores principales: | Wu, Jia-Yi, Zhang, Zhi-Bo, Zhou, Jian-Yin, Ke, Jing-Peng, Bai, Yan-Nan, Chen, Yu-Feng, Wu, Jun-Yi, Zhou, Song-Qiang, Wang, Shuang-Jia, Zeng, Zhen-Xin, Li, Yi-Nan, Qiu, Fu-Nan, Li, Bin, Yan, Mao-Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521320/ https://www.ncbi.nlm.nih.gov/pubmed/37767067 http://dx.doi.org/10.1159/000528356 |
Ejemplares similares
-
Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Wu, Jia-Yi, et al.
Publicado: (2021) -
Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A multicenter retrospective study
por: Wu, Jun-Yi, et al.
Publicado: (2022) -
Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy
por: Luo, Meng-Chao, et al.
Publicado: (2023) -
Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
por: Wang, Yan-Yu, et al.
Publicado: (2023) -
Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus
Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular
Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
por: Wang, Jinfeng, et al.
Publicado: (2023)